header image

Page 42«..1020..41424344..5060..»

Archive for Pet Stem Cell Therapy

Canine Stem Cell Therapy Market: Industry Statistics and Facts Helps to Flourish Industry Rapidly QYR | VETSTEM BIOPHARMA, Cell Therapy Sciences,…

LOS ANGELES, United States: Considering the growth of the global market, QY Research has recently published a report, titled Global Canine Stem Cell Therapy Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Canine Stem Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Canine Stem Cell Therapy market include: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet Canine Stem Cell Therapy

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1916703/global-canine-stem-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Canine Stem Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Canine Stem Cell Therapy Market Segment By Type:

Allogeneic Stem CellsAutologous Stem cells Canine Stem Cell Therapy

Global Canine Stem Cell Therapy Market Segment By Application:

Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Canine Stem Cell Therapy market.

Key companies operating in the global Canine Stem Cell Therapy market include VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet Canine Stem Cell Therapy

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1916703/global-canine-stem-cell-therapy-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Canine Stem Cell Therapy Revenue1.4 Market by Type1.4.1 Global Canine Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Allogeneic Stem Cells1.4.3 Autologous Stem cells1.5 Market by Application1.5.1 Global Canine Stem Cell Therapy Market Share by Application: 2020 VS 20261.5.2 Veterinary Hospitals1.5.3 Veterinary Clinics1.5.4 Veterinary Research Institutes1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Canine Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Canine Stem Cell Therapy Growth Trends by Regions2.2.1 Canine Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Canine Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Canine Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Canine Stem Cell Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Canine Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Canine Stem Cell Therapy Players by Market Size3.1.1 Global Top Canine Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Canine Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Canine Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Canine Stem Cell Therapy Market Concentration Ratio3.2.1 Global Canine Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Canine Stem Cell Therapy Revenue in 20193.3 Canine Stem Cell Therapy Key Players Head office and Area Served3.4 Key Players Canine Stem Cell Therapy Product Solution and Service3.5 Date of Enter into Canine Stem Cell Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Canine Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Canine Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Canine Stem Cell Therapy Market Size by Application (2015-2020)5.2 Global Canine Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Canine Stem Cell Therapy Market Size (2015-2020)6.2 Canine Stem Cell Therapy Key Players in North America (2019-2020)6.3 North America Canine Stem Cell Therapy Market Size by Type (2015-2020)6.4 North America Canine Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Canine Stem Cell Therapy Market Size (2015-2020)7.2 Canine Stem Cell Therapy Key Players in Europe (2019-2020)7.3 Europe Canine Stem Cell Therapy Market Size by Type (2015-2020)7.4 Europe Canine Stem Cell Therapy Market Size by Application (2015-2020) 8 China8.1 China Canine Stem Cell Therapy Market Size (2015-2020)8.2 Canine Stem Cell Therapy Key Players in China (2019-2020)8.3 China Canine Stem Cell Therapy Market Size by Type (2015-2020)8.4 China Canine Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Canine Stem Cell Therapy Market Size (2015-2020)9.2 Canine Stem Cell Therapy Key Players in Japan (2019-2020)9.3 Japan Canine Stem Cell Therapy Market Size by Type (2015-2020)9.4 Japan Canine Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Canine Stem Cell Therapy Market Size (2015-2020)10.2 Canine Stem Cell Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Canine Stem Cell Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Canine Stem Cell Therapy Market Size by Application (2015-2020) 11 India11.1 India Canine Stem Cell Therapy Market Size (2015-2020)11.2 Canine Stem Cell Therapy Key Players in India (2019-2020)11.3 India Canine Stem Cell Therapy Market Size by Type (2015-2020)11.4 India Canine Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Canine Stem Cell Therapy Market Size (2015-2020)12.2 Canine Stem Cell Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Canine Stem Cell Therapy Market Size by Type (2015-2020)12.4 Central & South America Canine Stem Cell Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 VETSTEM BIOPHARMA13.1.1 VETSTEM BIOPHARMA Company Details13.1.2 VETSTEM BIOPHARMA Business Overview13.1.3 VETSTEM BIOPHARMA Canine Stem Cell Therapy Introduction13.1.4 VETSTEM BIOPHARMA Revenue in Canine Stem Cell Therapy Business (2015-2020))13.1.5 VETSTEM BIOPHARMA Recent Development13.2 Cell Therapy Sciences13.2.1 Cell Therapy Sciences Company Details13.2.2 Cell Therapy Sciences Business Overview13.2.3 Cell Therapy Sciences Canine Stem Cell Therapy Introduction13.2.4 Cell Therapy Sciences Revenue in Canine Stem Cell Therapy Business (2015-2020)13.2.5 Cell Therapy Sciences Recent Development13.3 Regeneus13.3.1 Regeneus Company Details13.3.2 Regeneus Business Overview13.3.3 Regeneus Canine Stem Cell Therapy Introduction13.3.4 Regeneus Revenue in Canine Stem Cell Therapy Business (2015-2020)13.3.5 Regeneus Recent Development13.4 Aratana Therapeutics13.4.1 Aratana Therapeutics Company Details13.4.2 Aratana Therapeutics Business Overview13.4.3 Aratana Therapeutics Canine Stem Cell Therapy Introduction13.4.4 Aratana Therapeutics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.4.5 Aratana Therapeutics Recent Development13.5 Medivet Biologics13.5.1 Medivet Biologics Company Details13.5.2 Medivet Biologics Business Overview13.5.3 Medivet Biologics Canine Stem Cell Therapy Introduction13.5.4 Medivet Biologics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.5.5 Medivet Biologics Recent Development13.6 Okyanos13.6.1 Okyanos Company Details13.6.2 Okyanos Business Overview13.6.3 Okyanos Canine Stem Cell Therapy Introduction13.6.4 Okyanos Revenue in Canine Stem Cell Therapy Business (2015-2020)13.6.5 Okyanos Recent Development13.7 Vetbiologics13.7.1 Vetbiologics Company Details13.7.2 Vetbiologics Business Overview13.7.3 Vetbiologics Canine Stem Cell Therapy Introduction13.7.4 Vetbiologics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.7.5 Vetbiologics Recent Development13.8 VetMatrix13.8.1 VetMatrix Company Details13.8.2 VetMatrix Business Overview13.8.3 VetMatrix Canine Stem Cell Therapy Introduction13.8.4 VetMatrix Revenue in Canine Stem Cell Therapy Business (2015-2020)13.8.5 VetMatrix Recent Development13.9 Magellan Stem Cells13.9.1 Magellan Stem Cells Company Details13.9.2 Magellan Stem Cells Business Overview13.9.3 Magellan Stem Cells Canine Stem Cell Therapy Introduction13.9.4 Magellan Stem Cells Revenue in Canine Stem Cell Therapy Business (2015-2020)13.9.5 Magellan Stem Cells Recent Development13.10 ANIMAL CELL THERAPIES13.10.1 ANIMAL CELL THERAPIES Company Details13.10.2 ANIMAL CELL THERAPIES Business Overview13.10.3 ANIMAL CELL THERAPIES Canine Stem Cell Therapy Introduction13.10.4 ANIMAL CELL THERAPIES Revenue in Canine Stem Cell Therapy Business (2015-2020)13.10.5 ANIMAL CELL THERAPIES Recent Development13.11 Stemcellvet10.11.1 Stemcellvet Company Details10.11.2 Stemcellvet Business Overview10.11.3 Stemcellvet Canine Stem Cell Therapy Introduction10.11.4 Stemcellvet Revenue in Canine Stem Cell Therapy Business (2015-2020)10.11.5 Stemcellvet Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the rest here:
Canine Stem Cell Therapy Market: Industry Statistics and Facts Helps to Flourish Industry Rapidly QYR | VETSTEM BIOPHARMA, Cell Therapy Sciences,...

Two Families Receive Keys to Their New Home as Part of Habitat for Humanity Mauis Housing Program – Maui Time

Justin Dudoit and Christina Cyr of Habitat for Humanity Maui with the Blando family

Habitat for Humanity Maui completed two more homes in their affordable housing project in Lahaina.

Both homes are located in the Kahoma Residential Subdivision and feature two and four-bedroom floorplans ranging from 864 to 1,200 square feet. The family partners are longtime Lahaina residents and had over 44 family members and friends, in addition to community volunteers, who helped with the home-builds.

We never thought it would be possible to own a home, especially in these trying times, so this is our dream come true, said new homeowner, Lei Blando. Working with Habitat for Humanity Maui and alongside the community was an exciting experience. Weve made some lifelong friends and its been an amazing journey.

Helping to make the dream of homeownership a reality for these families is what Habitat for Humanity Maui is all about, said Yvonne McClean, Community Relations Director. We were able to bring people together to build homes, community, and hope during this pandemic and it would not have been possible without everyones help, she said.

Year to date, Habitat for Humanity Maui has completed four homes in the Kahoma Residential Subdivision and is projecting to finish this development by the end of the year.

To learn more about Habitat for Humanity Maui, or for ways you can help, contact Yvonne McClean at (808) 242-1140 or yvonne@habitat-maui.org.

comments

See the rest here:
Two Families Receive Keys to Their New Home as Part of Habitat for Humanity Mauis Housing Program - Maui Time

The Journey Back: Three Horses Go From Rehab to Recovery – TheHorse.com

How three equine athletes returned from injury to the show ring

At some point in your horse care journey, youve likely ridden a beautiful round, brought your horse in from turnout, or unloaded him from the trailer and realized something was off. Maybe it was a lame step or the slightest bit of swelling but, either way, it prompted a call to your veterinarian. If you were lucky, the root cause was something minor that would resolve with time off and anti-inflammatories. With the more challenging cases, however, you and your veterinarian might have pursued further diagnostics to determine the cause.

After reaching a diagnosis and settling on a treatment plan, you began the arduous process of healing and rehabilitation. This stage can be trying for even the most patient equestrian. But, with a good equine care team and some time, it can be smooth and fruitful.

To see what effective rehabilitation looks like, we found three real-life examples of equine athletes that made full recoveries from their injuries. Well share each ones diagnostic challenges, rehab modalities, and recovery details.

Chanel, a 10-year-old Quarter Horse mare competing in Western pleasure, had been struggling for years with a nagging intermittent left front lameness. Her owner and veterinarian managed this with routine coffin joint corticosteroid injections for about two years. However, the injections ultimately proved to be ineffective at keeping Chanel completely sound and comfortable, so she was referred to Carrie Schlachter, VMD, Dipl. ACVSMR, who founded and designed Circle Oak Equine Sports Medicines rehabilitation and fitness programs and also founded Animals In Motion, a practice that focuses on integrative sports medicine, rehabilitation, and injury prevention.

The case was pretty routine, says Schlachter. We nerve-blocked (used local anesthesia to numb and pinpoint the painful area) her foot, then we X rayed the area, and the X rays showed some mild abnormality in her coffin bone. We recommended an MRI so we could look at the area more deeply.

The MRI showed that Chanel actually had two injuries to her left front foot. The first was mild coffin bone bruising and remodeling in the area we had been looking at radiographically, Schlachter says. But, on the opposite side of the foot, she also had a collateral ligament injury. Collateral ligaments are located on either side of most joints.

This was the aha! moment, she says: Without the MRI I wouldnt have known about the collateral ligament injury so, because the owners were willing to do the MRI, I was not only able to confirm my diagnosis of the bone bruising and remodeling but I was also able to see the reason for it.

Chanel had likely been compensating for the collateral ligament injury by bearing more weight on one side of her foot, creating the bruising in the coffin bone. The injections helped initially because they suffused the area with steroids, reducing inflammation and allowing her to continue working soundly for a brief period.

With a diagnosis in place, Schlachter recommended putting Chanel in a bar shoe to support and stabilize the collateral ligament and the coffin bone. She and her team also injected the coffin joint and the collateral ligament with autologous protein solution (a biologic therapy that stimulates the bodys production of anti-inflammatory mediators and growth factors) and treated the area with extracorporeal shock wave therapy (believed to improve new blood vessel growth, recruit mesenchymal stem cells, and have pain relieving effects).

Schlachter also recommended for Chanel a controlled exercise program, which she modifies to meet the needs of different injuries and disciplines but typically involves:

Two months post-diagnosis, Schlachter reevaluated Chanel. At that point she was 80-90% better, so we allowed her to be walked under saddle for the next two months, she says. When we looked at her again at the four-month mark, she was 100% sound, so we started her on some trot work.

Once she was sound at the canter, Chanel began working back into training. Eight months post-diagnosis she was still sound and back in the show ring. She is now free of bar shoes, and her only maintenance since recovering has been a round of hock and sacroiliac joint injections to manage normal wear and tear.

Chanel was a wonderful patient, Schlachter says. She is the picture perfect example of what a good diagnosis, good treatment, compliant owners, and a well-behaved horse can do.

Melissa King, DVM, PhD, Dipl. ACVSMR, is an associate professor at the Colorado State University (CSU) Veterinary Teaching Hospital, in Fort Collins, where she specializes in equine sports medicine and rehabilitation. King treated JR, a 16-year-old Thoroughbred who had shown as a four-star eventer. From repetitive use in his job, JR developed an insertional lesion in his deep digital flexor tendon (DDFT, which runs from the knee down the back of the leg and around the navicular bone, attaching to the coffin bone) and a second, discrete tear at the pastern level. This article continues in the August 2020 issue of The Horse: Your Guide to Equine Health Care. Subscribe now and get an immediate download of the issue to continue reading. Current magazine subscribers can access the digital edition here.

View original post here:
The Journey Back: Three Horses Go From Rehab to Recovery - TheHorse.com

Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans – Cancer Therapy Advisor

Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States. In 2020, an estimated 77,240 Americans will be diagnosed with the disease and about 20,000 people will die from it.1 Seventy-two percent of patients live for at least 5 years after diagnosis.2 However, the success of treatment varies widely across the many subtypes of NHL. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common subtype, have a 5-year survival rate of 63% for all disease stages combined. By contrast, follicular lymphoma (FL) has a 5-year survival rate of 88% for all stages combined. Patients with mantle cell lymphoma, one of the more difficult-to-treat subtypes, have an average survival time of less than 5 years.3

But the treatment landscape is transforming across the entire spectrum of NHL. Novel immunotherapies and small molecule inhibitors are offering both previously treated and untreated patients entirely new options and new combinations. At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, researchers led by Jeremy Abramson, of Massachusetts General Hospital in Boston, provided a compelling overview of these new and upcoming treatments.4 Their overview, published in the ASCO Educational Book, offered a detailed and vital look at the present and future of NHL treatment.

CAR T-cell immunotherapy has been hailed as a major game-changer for some blood cancers.5 For aggressive B-cell lymphomas, such as DLBCL, anti-CD19 chimeric antigen receptor T cells (CAR-T) are a new option for patients who have relapsed following chemoimmunotherapy or autologous stem cell transplant (ASCT). For this patient group, which has a median overall survival of about 4 months, anti-CD19 CAR-T agents have elicited durable remissions in about 40% of patients.5-7 Clinical trial data has led to the approval of axicabtagene, ciloleucel, and tisagenlecleucel by both the US Food and Drug Administration and the European Medicine Agency. CAR T-cells offer curative intent therapy to patients with relapsed DLBCL who are not eligible for stem cell transplant, Dr Abramson told Cancer Therapy Advisor. Previously these patients only had palliative options available.

Some clinicians envision CAR-T as a potential first-line therapy for patients with DLBCL who relapsed after first-line chemoimmunotherapy. These patients, noted Anton Hagenbeek, MD, PhD, professor of Hematology at Amsterdam University Medical Centers, who was not involved with the review paper, represent one of the highest unmet needs in the treatment of lymphoma to date. And Helen Heslop, MD, who directs the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, noted that trials for first-line CAR-T therapy are already underway in acute lymphoblastic leukemia. Not everyone sees this potential. First-line treatment in NHL is generally very effective and much less expensive than CAR T-cells, explained Edward Copelan, MD, who chairs the Department of Hematologic Oncology and Blood Disorders at Carolinas Healthcare System in Charlotte, North Carolina, and who was not an author of the review. Though Dr Copelan emphasized that patients at extremely high risk of relapse following standard immunochemotherapy may respond well to CAR-T therapy.

Dr Abramson and co-authors highlighted a difficult conundrum with regard to DLBCL. Although the addition of rituximab to cyclophosphamide, doxorubicin, hydrochloride, and vincristine sulfate (CHOP) chemotherapy is curative for most patients, the number of patients who may be cured after relapse has declined. Thus improvements in second-line therapy are desperately needed. Several clinical trials are currently evaluating anti CD19 CAR-T for primary refractory or early relapsed aggressive B-cell lymphoma compared with traditional salvage therapy or ASCT. The same approach is being studied for relapsed DLBCL patients who are not transplant candidates.

Whether CAR-T therapy will find a place on the first line of care is another current question. The cost and logistics of CAR-T therapy make it unlikely that this approach will replace R-CHOP as the standard initial treatment, Dr Abramson and colleagues noted. I do not think CAR T-cells will replace frontline chemotherapy, Dr Abramson said. However, the authors note that for patients who do not respond well to initial treatment, such an approach may make sense a possibility that is now being examined in the clinical trial setting. Dr Hagenbeek is more certain about the first-line role for CAR-T therapy, based on the dismal prognosis of DLBCL that is refractory to R-CHOP.

On the subject of CAR-T therapy as first-line therapy, the authors pay special attention to so-called double-hit lymphomas (DHLs), also known as double expressor lymphomas. According to a multicenter study published in 2017, R-CHOP is curative for more patients than conventional wisdom has held.9 Clinical trials are currently investigating the use of anti-CD19 CAR-T early for patients who consistently test positive for disease on PET scans during initial therapy, though Dr Abramson and colleagues call for caution with this approach because the prognostic value of PET/CT scans is controversial. Dr Hagenbeek is optimistic about the potential for CAR-T therapy to improve the prognosis for patients with double- and even triple-hit lymphomas, if applied in the first complete, PET-negative metabolic remission. Because these patients have a relatively small tumor load, this approach could, said Dr. Hagenbeek, completely eradicate minimal residual disease. Its the double-hit patients who Dr Copelan sees as the likeliest candidates for first-line CAR T-cell treatment.

Excerpt from:
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor

Global Canine Stem Cell Therapy Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast…

Global Canine Stem Cell Therapy Market Size, Status and Forecast 2020-2026

In 2019, the global Canine Stem Cell Therapy Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

Canine Stem Cell Therapy Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Canine Stem Cell Therapy Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The Canine Stem Cell Therapy Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Canine Stem Cell Therapy Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-153387

Top key players @ VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, and Stemcellvet

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Canine Stem Cell Therapy Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Canine Stem Cell Therapy Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Canine Stem Cell Therapy Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Canine Stem Cell Therapy Market?

What are the key market trends impacting the growth of the Global Canine Stem Cell Therapy Market?

What are the challenges to market growth?

Who are the key vendors in the Global Canine Stem Cell Therapy Market?

What are the market opportunities and threats faced by the vendors in the Global Canine Stem Cell Therapy Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Canine Stem Cell Therapy Market;

3.) The North American Canine Stem Cell Therapy Market;

4.) The European Canine Stem Cell Therapy Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Canine Stem Cell Therapy Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-153387

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Read more here:
Global Canine Stem Cell Therapy Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast...

Is Lab-Grown Meat Healthy and Safe to Consume? – One Green Planet

It goes by many names: cultured, in vitro, cell-based, cultivated, lab-grown meat, etc. As the names imply, it is a meat alternative made in a lab via animal cells and a cultured medium, like fetal bovine serum or a proprietary mix of sugars and salts. Several companies around the world are promoting this new technique as a way to cultivate a meat alternative that is supposedly cleaner and safer than traditional meat.

(We are only looking at those products that culture cells taken from animals into a new meat-like formulation. There are many other products that culture plant, fungi, or algal cells into a meat substitute, but we are not reviewing them here.)

29 companies are planning to bring lab-cultured meat to market in the form of chicken, beef, pork, seafood, pet food, and beyond. These companies include Memphis Meats, Aleph Farms, Mosa Meat, Meatable, SuperMeat, and Finless Foods. These companies are backed by huge investments from meat industry corporations (Cargill and Tyson), venture capitalist firms (Blue Yard Capital, Union Square Ventures, S2G Ventures, and Emerald Technology Ventures), and billionaires (such as Bill Gates and Richard Branson).

While the hype is certainly there, is lab-cultured meat actually better? Its proponents tout it as an environmentally responsible, cruelty-free, and antibiotic-free alternative to current meat production. While the goal of producing sustainable meat without killing animals is admirable, lab-cultured meat is in its infancy and the science behind the production methods requires more scrutiny.

Of particular concern is the genetic engineering of cells and their potential cancer-promoting properties. To be able to better assess whether the products are being produced by methods that involve genetic engineering and use genetic constructs (called onco-genes, typically used to make stem cells keep growing; this is not a problem for lab experiments, but could be for food products) that might encourage cancer cells, we need more information on how the cells are engineered and kept growing. Many of the companies are claiming this information is confidential and a business secret. These companies are not yet patenting their production processes wherein this information would be more fully disclosed. Some suggest that the production will follow the FDA cell culture guidelines, but theFDAs cell culture guidelines do not apply to this because theyre not designed for food.

To produce lab-cultured meat, many producers extract animal cells from living animals. This is typically done via biopsy, a painful and uncomfortable procedure that uses large needles. If a company could scale up with this method, it would require a consistent supply of animals from which to acquire cells and innumerable painful extractions. To make the cell-based product more consistent, the producer may biopsy the same animal many times for the cells that growing meat requires.

Growing animal cells (typically muscle cells) also requires a growth medium. When lab-cultured meat production first began, companies depended on fetal bovine serum (FBS) as a growth medium. Producing FBS involves extracting blood from the fetus of a pregnant cow when the cow is slaughtered.

Given its high cost, it appears that FBS is usually only used during small-scale lab trials. Additionally, increasing production capacity using FBS comes with its own set of concerns. Even disregarding the high cost of FBS, non-genetically engineered animal muscle cells only proliferate or increase to a certain degree. In order to overcome this limitation, large companies such as Mosa Meats and Memphis Meats claim theyve found an FBS alternative that does not involve animals along with an effective way to expand production. For Memphis Meats, this process involves the utilization of abioreactor and the creation of immortal cell lines.

Curious about how we make our Memphis Meat? See below! #sogood pic.twitter.com/co5d7OY0bI

Memphis Meats (@MemphisMeats) May 8, 2018

These companies are using a bioreactor essentially a very large vessel for containing biological reactions and processes to implement a scaffold-based system to grow meat, which uses a specific structure for cells to grow on and around. The scaffolding helps the cells differentiate into a specific meat-like formation. Researchers cite using cornstarch fibers, plant skeletons, fungi, and gelatin as common scaffold materials. Instead of animal muscle cell precursors (otherwise known as myosatellites), researchers have been using cultured stem cells. This distinction is important because extracted muscle cells will only proliferate to a certain extent. Companies are trying cultured stem cells as an alternative type of cell(s) that could proliferate exponentially so that they could scale up production, and later differentiate the cells into the various cell types that make up animal meat (muscle, fat, and blood cells) in a bioreactor.

In this process, the stem cells still come from animals or animal embryos, but what differentiates the two methods is that in the scaffold-based system, the cells can be genetically engineered to proliferate indefinitely. These cells are otherwise known as pluripotent (which make many kinds of cells, like stem cells) or totipotent (which make every kind of cell, as do embryos). This would greatly expand a companys capacity to make lab-cultured meat, but the methods by which companies make these cells proliferate come with human health and food safety ramifications.

While the FDA has previously reviewed enzymes, oils, algal, fungal, and bacterial products grown in microorganisms, these new animal cell-cultured products are much more complicated in structure and require a more thorough review. The scale required for making lab-cultured meat feasible for mass consumption will be the largest form of tissue engineering to exist and could introduce new kinds of genetically engineered cells into our diets. Further research will also be needed to conrm or dispel uncertainties over various potential safety issues. Candidate topics for research include the safety of ingesting rapidly growing genetically-modied cell lines, as these lines exhibit the characteristics of a cancerous cell which include overgrowth of cells not attributed to the original characteristics of a population of cultured primary cells. If lab-cultured meat enters the market, there are several human health concerns associated with this new production method, specifically that these genetically-modified cell lines could exhibit the characteristics of a cancerous cell.

While these companies dont disclose much to the public about their processing methods, their public patents reveal the creation of oncogenic, or cancer-causing, cells.A Memphis Meats patent on the creation of modified pluripotent cell lines involves the activation or inactivation of various proteins responsible for tumor suppression. Another patent from JUST Inc. describes the utilization of growth factors as part of its growth medium. This process could promote the development of cancer-like cells in lab-cultured meat products. Additionally, it is possible certain growth factors can be absorbed in the bloodstream after digestion.

If they are using stem cells, cell-based meat companies need to pay attention to the risk of cancer cells emerging in their cultures. A research team from the Harvard Stem Cell Institute (HSCI), Harvard Medical School (HMS), and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard has found that as stem cell lines grow in a lab environment, they often acquire mutations in the TP53 (p53) gene, an important tumor suppressor responsible for controlling cell growth and division. Their research suggests that inexpensive genetic sequencing technologies should be used by cell-based meat companies to screen for mutated cells in stem cell cultures so that these cultures can be excluded.

Cancer-causing additives are prohibited in our food supply under the Delaney Clauses in the 1958 Food Additive Amendments and the 1960 Color Additive Amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA). These new rapidly growing cell lines might be considered color additives if they are being used to produce the color in the meat. The federal statutes regulating meat also prohibit the selling of animals with symptoms of illness, such as cancerous cells in meat. Regardless, all of these new ways of making cells that continue to grow or differentiate should require a safety assessment to determine if they contain cancerous cells before they can be sold.

In describing the scaffolding and growth media being used, lab-cultured meat companies need to be fully transparent about what ingredients theyre using. During the above-mentioned industry nonprofits presentation, the presenter suggested the growth media could be composed of a variety of different ingredients like proteins, amino acids, vitamins, and inorganic salts classified under the GRAS (Generally Recognized As Safe) process that allows companies to do their own testing and not submit to a new FDA food additive review. Since companies are not required to fully disclose the composition of their scaffolding or growth media, potentially exposing consumers to novel proteins and allergens, the new mixture of ingredients should be reviewed under a full FDA supervised food additive review, not GRAS.

Another major issue associated with processing methods using cell lines and/or culture medium is contamination. Unlike animals, cells do not have a fully functioning immune system, so there is a high likelihood of bacterial or fungal growth, mycoplasma, and other human pathogens growing in vats of cells. While lab-cultured meat companies emphasize that this type of meat production would be more sterile than traditional animal agriculture, its unknown how that is true without the use of antibiotics or some other pharmaceutical means of pathogenic control.

Based on commentary from various companies, antibiotic usage across the industry is still very unclear. While the industrys promoters have outlined many uses for antibiotics in lab-grown meat production in preventing contamination, they have not disclosed the amount of antibiotics being used in the various processes. Instead, they suggest that because mass production of lab-grown meat will be done in an industrial rather than lab setting, with bioreactors and tanks, there will be higher safety oversight than in medical labs. It is suggested that the many preventative measures in the industry will maintain a sterile boundary and deter antibiotic use in production. It remains a question of how a food production plant would be more sterile than a medical lab.

Some companies, such as Memphis Meats claim they are genetically engineering cell lines to be antibiotic-resistant, which would suggest they plan on using antibiotics, but dont want their meat cells to be affected. Problems with bacterial and viral contamination plague medical cell culture, so they generally use antimicrobials. Still, any large-scale production that requires antibiotic use even if just for a short-term duration should require such lab-cultured meat undergo even stricter USDA drug residue testing, pathogen testing, and FDA tolerance requirements than conventionally-produced meat. Many other companies claim they dont plan to use antibiotics in expanded production which begs the question, in addition to supposed sterile bioreactors, are they using other undisclosed processes to prevent contamination? For example, Future Meat Technologies describes the use of a special resin to remove toxins.

The companies have also not disclosed plans for how they will dispose of the toxins from bioreactors, scaffolding, and culture media like growth factors/hormones, differentiation factors, often including fetal calf serum or horse serum, and antimicrobials (commonly added to cultured cells to prevent bacterial and fungal contamination, particularly in long-term cultures). In conventionally-produced meat, animals dispose of these toxins in their urine and feces. If companies cant find a way for this meat to dispose of these toxins, they could potentially build up within the meat itself. Given the lack of clarity of these companies and their processes, there must be continuous monitoring of the cell lines and growth media/bioreactor for contaminants and some sort of standardization established across the industry to ensure safety.

The industry is new and the exact production process and inputs needed for large-scale, lab-cultured meat production are unknown (or not being disclosed by the companies). It is the responsibility of both FDA and USDA to ensure that all inputs used in production and the final product are safe for human and animal consumption. These agencies must ensure that lab-cultured meat is labeled appropriately, including if any of the product ingredients are genetically modified or if the ingredients are produced using unmodified cells from animals. These agencies must also ensure that this product doesnt introduce new allergens into the food supply, that any hormones or antibiotics used are not found at unsafe levels in the final product, and that the product doesnt contain any compounds or oncogenic (cancer-causing) cells that have not been approved for use in food.

Lab-cultured meat should not be allowed to use the Generally Recognized As Safe (GRAS) regulatory loophole wherein companies can hire their own experts to evaluate their products, often in secret without any notice to the public or FDA. GRAS is an inappropriate designation because the consensus among knowledgeable experts regarding the safety of lab-cultured meat does not yet exist. Instead, FDA should require that lab-cultured meat products be regulated more thoroughly as food additives. Meat companies should submit complete food additive petitions for each of the novel ingredients used to produce these meats as well as a final food approval petition for the entire product. The production facilities, like all meat processing plants, should then have USDA inspectors on-site monitoring the process and inspecting the meat. The USDA announced in August that it will start the process of developing regulations for these new kinds of meat. Adequate regulation will be necessary to address the concerns raised in this blog.

Overall, due to the novel nature of lab-cultured meat, the lack of transparency from the companies involved, and the myriad potential health risks to consumers, rigorous regulation of this product is vitally important. Join Center for Food Safetys mailing list to protect your right to safe food HERE >>

For those of you interested in eating more plant-based, we highly recommend downloading theFood Monster App with over 15,000 delicious recipes it is the largest plant-based recipe resource to help reduce your environmental footprint, save animals and get healthy! And, while you are at it, we encourage you to also learn about theenvironmentalandhealth benefitsof aplant-based diet.

Here are some great resources to get you started:

For more Animal, Earth, Life, Vegan Food, Health, and Recipe content published daily, subscribe to theOne Green Planet Newsletter! Lastly, being publicly-funded gives us a greater chance to continue providing you with high-quality content. Please considersupporting usby donating!

The rest is here:
Is Lab-Grown Meat Healthy and Safe to Consume? - One Green Planet

Unraveling the use of CBD in veterinary medicine – Jill Lopez

It was about the 3rd week into Bastions recovery from his TPLO surgery and he was already having a rough time. Bastion was a gregarious yellow Labrador who had his injured stifle about 25 days ago. Fortunately, his family elected for him to have his stifle surgically reconstructed. Initially, he had recovered well from surgery. But one day in particular, he presented to the hospital because he had a brief setback. He was limping far more severely than what would be normally expected at this stage of recovery.

The osteotomy from his surgery had not yet completely healed and he was still in the middle of his prescribed 5 weeks of exercise strict restriction. His family was trying their best but Bastion wasnt having it. He was too active at home and his humans were growing frustrated. Anti-anxiety medications had been dispensed but they were not given. Instead, his family had decided to give him CBD oil at home. When I asked why the prescribed medications had not been given, the client responded, I found CBD oil at the local farmers market and I figured it would work just as well.

Like Bastion, an increasing number of pets are receiving cannabidiol (CBD) supplements. The popularity of CBD continues to rise and many clients are incorporating CBD as part of the medication protocol for their pets, either as an adjunct or, as alternative treatment option.

Perhaps the initial interest in the benefits of CBD can be traced back to 1998, or possibly earlier, when scientists at the National Institutes of Health discovered that CBD could protect cells from oxidative stress. These findings fueled interest in the human medical field and, in large part, that appeal has been transmuted into veterinary medicine. The regard for this molecule has risen to such levels that in many homes, CBD is being used as the sole treatment option for a variety of medical conditions.

Veterinarians are becoming more fluent in the fascinating pharmacology regarding the use of this phytocannabinoid. A recent survey indicated that most veterinarians (61.5%) felt comfortable discussing the use of CBD with their colleagues, but only 45.5% felt comfortable discussing this topic with clients.1 Furthermore, veterinarians and clients in states with legalized recreational marijuana were more likely to talk about the use of CBD products to treat canine ailments than those in other states.2 Lastly, CBD was most frequently discussed as a potential treatment for pain management, anxiety and seizures.1 At first glance, the use of CBD has tangential or limited relevance in the world of veterinary surgery. However, as one takes a closer look at the putative, and proven benefits, it is clear that we are just scratching the surface of its therapeutic benefits. This article takes a brief dive into the world of CBD and its promise in the field of veterinary surgery.

Pain

Whether you perform surgery within a specialty discipline (oncology, orthopedics, neurology, soft tissue surgery, mixed animal, oral/dental, etc), or surgery is only a small part of your general practice, every veterinarian endeavors to aggressively manage pain. The first choice for pain relief among many clinicians are the medications that have been more extensively studied including, but not limited to, anti-inflammatories, gabapentinoids, opioids, local anesthetics, and other analgesics (acetaminophen, amantadine, cerenia etc). These medications or a combination thereof, have been prescribed to treat pain from orthopedic surgery, soft tissue surgery, surgical neuropathic conditions, pain from intestinal surgery, to name just a few. In the most basic schema, pain is divided into four categories: nociceptive pain (a response to damaged tissue), neuropathic pain (a response to directly-damaged sensory or spinal nerves), centralized pain (the result of pain signals being improperly amplified), and inflammatory pain.1 Cannabinoids may have a role to play in mediating all four of these types of pain states. When tissue is damaged, histamine, serotonin, TNF-alpha, IL-1-beta, IL-6, and Il -17 6, and interleukin 17 are released.2 Cannabinoids bind to the CB1 receptors and attenuate the pain signal by slowing down the release of those neurotransmitters.3 This process can take place locally or in the central nervous system.3 Cannabinoids have also been shown to inhibit the release of GABA, a well known neurotransmitter associated with pain.3 Although there is a paucity of clinical research on the use of CBD to treat postoperative pain in the veterinary medical setting, there has been heartening research conducted in humans. Indeed, National Academies of Sciences, Engineering, and Medicine concluded that there is, substantial evidence that cannabis is an effective treatment for chronic pain in adults.

Opioids have long been the go to option, or cornerstone of pain management, however, the potential for the adverse events associated with the use of opioids in veterinary patients is universally accepted.38 I have seen how distressing it can be for a family to see their pet experiencing any of the unpleasurable side effects of opioids including urine retention, delayed bowel movements, whining, panting, disorientation, or other manifestations of dysphoria. Those are just some of the challenges that clinicians face when using opioids for chronic pain management. Considering the ongoing consequences of the opioid epidemic, there is a search for pain management solutions that are innovative, prone to less adverse events, and are more effective. As the scientific community begins to evaluate the evidence for use of CBD , it is clear that more research is needed.

Anecdotal reports of CBDs efficacy as a pain reliever are ubiquitous but more are turning to scientific data for evidence of CBDs efficacy. A study in 2020 evaluating effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients found that over half of chronic pain patients (53%) reduced or eliminated their opioids within 8 weeks after adding CBD-rich hemp extract to their regimens.5 Almost all CBD users (94%) reported quality of life improvements.5 And in a recent study evaluating orally consumed cannabinoids for long-lasting relief of allodynia in a mouse model, found that cannabinoids reduced hyperalgesia and a similar effect was not found with morphine.4 Mouse vocalizations were recorded throughout the experiment, and mice showed a large increase in ultrasonic, broadband clicks after sciatic nerve injury, which was reversed by THC, CBD, and morphine.4 The study demonstrated that cannabinoids provide long-term relief of chronic pain states.4 If research shows that use of cannabinoids in animals, specifically, CBD, can help to decrease the use of opioids for pain management, that would help make more animals comfortable and potentially help to fight the tragic epidemic of human prescription opioid abuse. Further research is needed in a variety of species, specifically, both the canine and feline species.

Bone Healing

Both general veterinary practitioners and veterinary surgeons commonly diagnose and treat fractures. A large retrospective study of fracture incidence in dogs in North America has not been published since 1994; however, the findings from that study are still informative regarding the frequency of bone injuries. That study demonstrated that approximately 24% of all patients in the population studied over a 10 year period were affected by a disorder of the musculoskeletal system, with fractures contributing the largest proportion (over 29%) of all of the diagnosis of the appendicular skeletal system.7 Although that research is dated, the conclusions from this study - at the very least, indicate that fractures are commonplace in the clinical veterinary setting.7 Fracture repair has gradually become more straightforward due to improvements in technology. Because of these innovations, speciality surgeons and general practitioners who repair fractures have begun to see better surgical outcomes. So whether you primarily stabilize fractures with implants, or if external coaptation of fractures with the intention to refer (or perhaps as the primary means of fixation) is your treatment of choice, all veterinary practitioners aim to help fractured bones heal quickly. Despite these technological improvements, bone healing can be protracted or non existent with some fractures. There are a variety of options at a veterinarians disposal to kick-start the healing process but perhaps in the near future, CBD may be added to that armamentarium. The effect of CBD in fracture healing has been investigated evaluating bone callus formation in femur fractures in a rat model.8 The findings demonstrated enhanced biomechanical properties of healing fractures in those given CBD compared with a control group.8 This effect was not found in those only given 9-THC. Moreover, the bone forming effects (osteogenic) of CBD were weakened when test subjects were given equal amounts of CBD and 9-THC.6 Another in vivo research study indicated that when CBD is incorporated into a surface that promotes bone growth (osteoconductive scaffold) it can stimulate stem cell migration and osteogenic differentiation.9 Further studies are needed to better evaluate the role of CBD in healing and bone metabolism of companion animals so that these findings can be applied in the clinical setting.

Additionally, cannabis has been shown to be a useful addition in treatment plans optimized to improve bone health in laboratory studies. A study endeavored to more closely understand the role of CB2 receptors in maintaining bone health. CB2 receptors in bone cells have been linked to maintaining bone density and stimulating growth, and may therefore have a part in reversing the effects of osteoporosis.10 One study evaluating role of CB2 receptors, found that in mice whose genes had been altered to remove the CB1 or CB2 receptors, those that developed signs of bone weakness that were far more pronounced than those in the control group.12 Another study in 2009, investigated the relationship between CB2 expression and bone disease in humans. The study found that people with dysfunctional CB2 receptors to have significantly weaker hand bones.11

Arthritis

Osteoarthritis (OA) affects many dogs, large and small. Most often, OA is the consequence of a developmental orthopedic disease that often affects a single joint or a pair of joints, and, less often, affects multiple joints. It is axiomatic that Mother Nature likes symmetry thus developmental orthopedic diseases frequently affect both left and right joints. For example, hip dysplasia is reportedly bilateral in >60% of affected dog,s13 and elbow dysplasia is bilateral in approximately 50% of affected dogs.14 Osteoarthritis occurs secondary to a myriad of primary orthopedic conditions that affect a variety of joints including: the hip (most common causes of OA in the hip: hip dysplasia, Perthes disease); stifle (patellar luxation, cranial cruciate ligament disease, osteochondritis dissecans [OCD]); elbow (elbow dysplasia, elbow OCD, fragmentation of the medial coronoid process, incomplete ossification of the humeral condyle); shoulder (shoulder OCD, developmental shoulder subluxation); tarsus (OCD of the talus), and carpus (carpal laxity, carpal subluxation secondary to chondrodystrophy); and metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joint degenerative osteoarthritis (digital osteoarthritis) .

Cannabinoids were found to treat pain secondary to inflammation in a variety of studies on humans. Some of the most compelling research has shown that cannabis can reduce the inflammation in the joint caused in human patients diagnosed with immune mediated arthritis.15 One study found that cannabinoids could simultaneously reduce the secretion of cytokines involved in inflammation from one type of TH immune cells, which were being under-produced, while also increasing their numbers to correct their scarcity.15 Furthermore in a study in 2003, researchers found that plant-based cannabinoids could suppress the expression of interleukin-1betaone of the most prominent markers for inflammation in patients with rheumatoid arthritisby as much as 50%.16 And finally, in 2006, transdermal applications of CBD were shown to decrease biomarkers that can contribute to neurogenic inflammation in a sample of arthritic rats. 17

A report published in the journal of PAIN, lead by researchers at Baylor College of Medicine revealed the results of a large, double blinded, placebo controlled study on the positive effects CBD had in the fight against osteoarthritis.18 The study was designed with two main goals: The first portion of the research studied the effect CBD had on the inflammatory molecules and cells in mice.18 The second portion of the study, investigated whether CBD improved the quality of life in dogs diagnosed with osteoarthritis. In lab tests and in mouse models, CBD significantly decreased the production of natural chemicals that promote inflammation and it increased the natural chemicals that fight inflammation.18 Essentially, what they saw was a drop in proinflammatory cytokines and an increase in anti-inflammatory cytokines. 18 For dogs with osteoarthritis, CBD significantly decreased pain and increased mobility in a dose-dependent fashion. Importantly, A lower dose of liposomal CBD was as effective as the highest dose of nonliposomal CBD, indicating that the effect of CBD was quicker and more effective when CBD was delivered encapsulated in liposomes than without.18 Blood samples indicated no significant harmful side effects, or adverse events, over the 4-week analysis period.18 Although this study is very promising and it supports the safety and therapeutic potential of hemp-derived CBD for relieving arthritic pain in dogs, it is important to consult with your pets veterinarian before giving any supplement or medication.

In the veterinary population, use of cannabidiol and other alternative treatments may have the potential to obviate the need for other medications, and thus spare patients from adverse effects associated with their use. More likely, the use of cannabinoids could be additive or synergistic in a multimodal treatment strategy and could increase quality-of-life issues associated with painful arthritic conditions.

Intervertebral Disk Disease

As our patients age, discs in the spine also undergo degenerative changes. Thus, degeneration of intervertebral discs is evitable. This process of degeneration is multifactorial process and it involves hypoxia, inflammation, neoinnervation, accelerated catabolism, and reduction in water and glycosaminoglycan content.39 The magnitude and severity of disc degeneration can vary widely between patients. The most common locations of clinically relevant disc disease are located in the cervical spine, thoracolumbar spine, and the lumbosacral spine.40 Although there are various manifestations of disc disease, broad classifications of Hansen Type I and Type II are typically used to describe the condition. In short, disc material may either extrude (acute herniations) or protrude (chronic herniations), both of which compress the spinal cord which ultimately can cause pain, paresis, paralysis and other neurological deficits.40 The prevalence of thoracolumbar disc disease dogs has been estimated at 3.5%.40 Depending on the neurologic examination, diagnosis, severity, prognosis, and other factors, surgery may be recommended to decompress the spinal cord.

After surgical decompression, there are a host of challenges that the the patient, the family, and the surgeon, may have to work through including a potentially protracted recovery, recurrence of neurological signs, post surgical pain, spinal instability, urinary disorders, (cystitis, urinary tract infection, urinary retention, micturition disorders), ascending myelomalacia, and others.41 Could CBD play a part in helping to improve those affected by disc disease pre-, intra-, or post-operatively and what types of spinal disorders could benefit from CBD? A study conducted on the use of CBD in mice with degenerative disc disease showed promise in mitigating the effect of disc damage and wear.19 Instead of being ingested orally, CBD was injected at the site of the disc. Researchers investigated the effects of cannabidiol intradiscal injection using a combination of MRI and histological analyses.19 A puncture was created in the disc and then CBD was injected into the disc (30, 60 or 120 nmol) shortly after.19 The effects of intradiscal injection of cannabidiol were analyzed within 2 days by MRI.17 Fifteen days later, the group that received cannabidiol 120 nmol was resubmitted to MRI examination and then to histological analyses after the cannabidiol injection.19 What they found was that cannabidiol significantly decreased the effects of disc injury induced by the needle puncture.19 These results suggest that this compound could be useful in the treatment of intervertebral disc degeneration perhaps using a novel route of administration.

Unfortunately, the exact mechanism for how CBD oil helped protect disc damage is still being investigated. The hope is that the neuroprotective properties of cannabidiol can also be found in the study of canine and feline disc disease to ultimately improve functional recovery.

References:

Kogan L, Schoenfeld-Tacher R, et al. US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions. Front Vet Sci. 2018;5:338.

Abd-Elsayed A., Deer T.R. (2019) Different Types of Pain. In: Abd-Elsayed A. (eds) Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-99124-5_3

Manzanares J, Julian MD, Carrascosa A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes Curr Neuropharmacol. 2006 Jul; 4(3): 239257.

Abraham AD, Leung EJ, Brenden A, Wong BA, Rivera ZM, Kruse LC, et al. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. 2020 Jun;45(7):1105-1114. doi: 10.1038/s41386-019-0585-3. Epub 2019 Dec 7.

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020 Jan;132(1):56-61. doi:10.1080/00325481.2019.1685298. Epub 2019 Nov 12.

Abraham AD, Leung EJ, Wong BA, Rivera ZM, Kruse LC, Clark JJ, Land BB. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. Neuropsychopharmacology. 2020: 45:11051114.

Johnson, J., Austin, C., & Breur, G. Incidence of Canine Appendicular Musculoskeletal Disorders in 16 Veterinary Teaching Hospitals from 1980 through 1989. Veterinary and Comparative Orthopaedics and Traumatology, 07(02), 5669. (1994). doi:10.1055/s-0038-1633097

Kogan NM, Melamed E, Wasserman E. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts J Bone Miner Re. 2015 Oct;30(10):1905-13. doi: 10.1002/jbmr.2513. Epub 2015 May 10.

Kamali, A., Oryan, A., Hosseini, S., Ghanian, M. H., Alizadeh, M., Baghaban Eslaminejad, M., & Baharvand, H. Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Materials Science and Engineering: (2019). C, 101, 6475. doi:10.1016/j.msec.2019.03.070

Bab I, Zimmer A. Cannabinoid Receptors and the Regulation of Bone Mass. British Journal of Pharmacology. 2007 153:182-188 doi:10.1038/sj.bjp.0707593

I. Idris, A. Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology. 2010. 8(3), 243253. doi:10.2174/157015910792246173

Meliha Karsak et al. The Cannabinoid Receptor Type 2 (CNR2) Gene Is Associated with Hand Bone Strength Phenotypes in an Ethnically Homogeneous Family Sample. Human Genetics. 2009. 5:629-36 doi:10.1007/s00439-009-0708-8.

Loder, R. T., & Todhunter, R. J. The Demographics of Canine Hip Dysplasia in the United States and Canada. Journal of Veterinary Medicine. 2017 115. doi:10.1155/2017/5723476

ONeill DG, Brodbelt DC, Hodge R,. Church DB, Meeson RL. Epidemiology and clinical management of elbow joint disease in dogs under primary veterinary care in the UK. Canine Medicine and Genetics. 2020 volume 7:1

Susan H. Pross et al. Differential Suppression of T-cell Subpopulations by THC (delta-9- tetrahydrocannabinol). International Journal of Immunopharmacology 12, no. 5 (1990): 539-44. doi:10.1016/0192-0561(90)90118-7

Robert B. Zurier et al. Suppression of Human Monocyte Interleukin-1 Production by Ajulemic Acid, a Nonpsychoactive Cannabinoid. Biochemical Pharmacology. 2003 4:649-55. doi:10.1016/s0006-2952(02)01604-0.

D.c. Hammell et al. Transdermal Cannabidiol Reduces Inflammation and Pain-related Behaviours in a Rat Model of Arthritis. European Journal of Pain. 2015 6:936-48. doi:10.1002/ejp.818

Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Halpert, M. M. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. 2020. Pain. doi:10.1097/j.pain.0000000000001896

Silveira, J. W., Issy, A. C., Castania, V. A., Salmon, C. E. G., Nogueira-Barbosa, M. H., Guimares, et al. Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. 2014. PLoS ONE 9:12 doi:10.1371/journal.pone.0113161

Yam, M., Loh, Y., Tan, C., Khadijah Adam, S., Abdul Manan, N., & Basir, R. . General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation. International Journal of Molecular Sciences. 2018 19(8), 2164. doi:10.3390/ijms19082164

Costigan, M., Scholz, J., & Woolf, C. J. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annual Review of Neuroscience. 2009 32(1), 132. doi:10.1146/annurev.neuro.051508.135531

Arora A, Taliyan R, Sharma PL. Ameliorative Potential of Cannabis Sativa Extract on Diabetes Induced Neuropathic Pain in Rats. International Journal of Pharmaceutical Sciences and Research 1. 2010 https://www.researchgate.net/publication/216536386_Ameliorative_potential_of_cannabis_sativa_extract_

Mark S. Wallace et al., Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. 2015. Pain 16(7): 616-27 doi:10.1016/j.jpain.2015.03.008.

Gruen, M. E., Roe, S. C., Griffith, E., Hamilton, A., & Sherman, B. L.. Use of trazodone to facilitate postsurgical confinement in dogs. Journal of the American Veterinary Medical Association. (2014) 245(3), 296301. doi:10.2460/javma.245.3.296

Serra, G., & Fratta, W. A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health. 2007. 3(1), 25. doi:10.1186/1745-0179-3-25

Kim, E. J., Pellman, B., & Kim, J. J. Stress effects on the hippocampus: a critical review. Learning & Memory. 2015. 22(9), 411416. doi:10.1101/lm.037291.114

Demirakca, T., Sartorius, A., Ende, G., et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. 2010. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2010.09.020

Mateus M. Bergamaschi et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Nave Social Phobia Patients. Neuropsychopharmacology. 2011 36(6):1219-26 doi:10.1038/npp.2011.6.

Jos Alexandre S Crippa et al. Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report. Journal of Psychopharmacology. 2010. 25: 1doi:10.1177/0269881110379283.

National Academies of Sciences, Engineering, and Medicine, 120.

Zieba, J., Sinclair, D., Sebree, T., Bonn-Miller, M., Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP1-independent mechanism. Pharmacology Biochemistry and Behavior. 2019. doi:10.1016/j.pbb.2019.05.002

Pamplona, F. A., da Silva, L. R., & Coan, A. C. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. 2018. Frontiers in Neurology, 9. doi:10.3389/fneur.2018.00759

Palmieri B, Laurino C, Vadal M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Mar-Apr 2019;170(2):e93-e99. doi: 10.7417/CT.2019.2116.

Sangiovanni, E., Fumagalli, M., Pacchetti, B., Piazza, S., et al.. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. (2019). Phytotherapy Research. doi:10.1002/ptr.6400

B. Van Klingeren and M. Ten Ham. Antibacterial Activity of 9-tetrahydrocannabinol and Cannabidiol. 1976. 42(1-2): 9-12 doi:10.1007/bf00399444.

Giovanni Appendino et al. Antibacterial Cannabinoids From Cannabis Sativa: A StructureActivity Study. 2008. Journal of Natural Products 71(8):1427-430, doi:10.1021/np8002673

McIver, V., Tsang, A., Symonds, N., Perkins, N., et al. Effects of topical treatment of cannabidiol extract in a unique manuka factor 5 manuka honey carrier on second intention wound healing on equine distal limb wounds: a preliminary study. 2020. Australian Veterinary Journal. doi:10.1111/avj.12932

White, D. M., Mair, A. R., & Martinez-Taboada, F. Opioid-free anaesthesia in three dogs. Open Veterinary Journal. 2017 7(2), 104. doi:10.4314/ovj.v7i2.5

Hansen T, Smolders LA, Tryfonidou MA, et al: The Myth of Fibroid Degeneration in the Canine Intervertebral Disc: A Histopathological Comparison of Intervertebral Disc Degeneration in Chondrodystrophic and Nonchondrodystrophic Dogs. Vet Pathol 2017 Vol 54 (6) pp. 945-952.

40. Jeffery ND, Levine JM, Olby NJ, et al: Intervertebral disk degeneration in dogs: consequences, diagnosis, treatment, and future directions. J Vet Intern Med 2013 Vol 27 (6) pp. 1318-33.

41. Balducci F, Canal S, Contiero B, et al: Prevalence and Risk Factors for Presumptive Ascending/Descending Myelomalacia in Dogs after Thoracolumbar Intervertebral Disk Herniation. J Vet Intern Med 2017 Vol 31 (2) pp. 498-504.

Read this article:
Unraveling the use of CBD in veterinary medicine - Jill Lopez

Show speciesism the door – The Malaysian Insight

IF the Covid-19 pandemic has taught us anything, it is that deforestation, the exploitation and consumption of wildlife, and intensive animal agriculture all increase the risk of zoonotic diseases and threaten human health and well-being.

Society is aware of the link between animal exploitation and disease outbreaks, which is the reason why China announced a ban on wildlife trade in an effort to contain Covid-19. In the US and elsewhere, sales of plant-based meat alternatives increased by more than 200% during the coronavirus lockdown. In the Netherlands, the mink fur industry went into an early shutdown after the animals were found to have contracted the virus and transmitted it to humans. There are now calls to shut down mink farms in Spain and the US, too.

It would be premature to celebrate these as victories. Humans have a short memory, and human desires and appetites are often alarmingly disconnected from what their intellect knows to be beneficial to health, social justice, and animal and environmental well-being.

Humans in general rarely question their relationship with animals and the natural world, and this is attributable to speciesism, that is, the assumption of human superiority and an inherent right to use, exploit and consume animals. In spite of the fact that scientific evidence and historical data strongly indicate that six out of 10 known infections, and three out of four emerging infectious diseases, originate from animals, there is still widespread resistance against ending animal agriculture, and the breeding of animals for the pet, sport hunting, entertainment and fur industries, with supporters of these industries arguing that it would put too many people out of work and cause economic losses. We know from the study of human history and civilisation that society is resilient and adaptable, and that industries and occupations have died out without causing significant or lasting damage.

Racism is what makes Western society believe that China ought to be pilloried for its wildlife trade and live animal wet markets. But, the same society thinks it is perfectly alright to confine calves in small enclosures, induce iron deficiency to produce veal, and confine and force-feed ducks and geese, inducing liver disease, to produce foie gras. Speciesism is what makes society understand that animal agriculture puts a huge strain on the planets resources, that animals in farms and laboratories suffer in ways that are not considered acceptable for even the worst of humans, and that humans can live healthy and productive lives without eating or exploiting animals, and yet, still choose to eat meat and maintain the status quo. Speciesism is also the reason why people throw birthday parties for their dogs and cats, and raise funds for tapirs and pandas, but think nothing of paying someone else to deplete our oceans and commit deforestation so that one can eat fish and steak, because the lives of certain species are valued more than others.

Humans know that in order to prevent pandemics and environmental disasters, we need to stop exploiting and interfering with animals and the natural world, and yet, our speciesist bias means that we are unwilling to give up the pleasure that comes with eating and confining animals, destroying wildlife habitats, and using animals for clothing, entertainment and sport. Humans sense of dominion and desire to maintain the appearance of being the master species mean that we continue to normalise violence and cruelty to animals, and trivialise their pain and suffering.

To move forward into a cleaner, healthier, greener and kinder future, we need to ask ourselves some hard questions about our relationship with other species. For too long, we have relied on the appeal-to-tradition fallacy that humans have always eaten meat as a justification to continue doing so. Just because something has always been done does not make it moral. We can agree that no amount of normalisation can make slavery, domestic violence or human trafficking a moral act, thus, we are also capable of making the connection that just because we have always eaten and exploited animals, it does not make these acts moral, justifiable or essential to human health and survival.

Further, it is true that humans have always eaten meat, but it is also true that previous pandemics have been linked to the consumption and exploitation of animals. The 1918 Spanish flu arose from the farming and consumption of pigs. Rabies in South America was transmitted by vampire bats to cattle, which then transmitted it to humans. The Nipah virus outbreak started when infected fruit bats transmitted it to farmed pigs. Scientists believe that HIV has its origins in the hunting of primates in Central African forests, while Ebola has been associated with hunting in Gabon and the Republic of the Congo. Where there is the consumption of meat and the destruction of the natural world, there will be disease outbreaks.

We need to question not only animal agriculture and meat consumption, but also the frequency and volume of the said consumption. As incomes and standards of living rise in Malaysia, our meat consumption, too, rises. Between 1981 and 2015, the consumption of beef in Malaysia rose from 23,000 metric tonnes to 250,000 metric tonnes. Between 1996 and 2015, the consumption of poultry rose from 666,000 metric tonnes to 1.59 million metric tonnes. Even if meat consumption was not a moral issue for people who lived two or three generations ago, it is imperative for us to now ask ourselves if it is necessary, appropriate, moral and harmless for us to continue to consume so much, and inflict so much suffering, pain and death. The more meat we eat, the more intensive and cruel the animal agriculture industry becomes in order to be efficient and profitable.

The technology already exists for us to consume meat that does not cause animal suffering, or harm our health or the environment. Clean meat, grown from harvested stem cells, is now reaching a scale of production where it will soon be as affordable as animal-based meat. Producing meat in laboratories requires less water, land and grain than livestock farming, and significantly reduces greenhouse gas emissions. Plant-based meat alternatives have already been in the Malaysian market for years, and most of these products have obtained halal certification and can be safely enjoyed by all. Thanks to advances in technology, much of the world, including Malaysia, has access to a wide variety of fruits, grains and vegetables, which can meet human dietary needs inexpensively. Considering that we can get all the nutrients and calories we need from non-animal sources, what is stopping us from making the transition?

There is a growing population of vegans and animal rights advocates who hold the strong moral view that there can be no justification for harming animals. But even holding the moderate view that we should kill fewer animals for food, and choose products and services that do not harm or exploit animals, will reduce the number of animals that suffer great pain and misery, and are killed to satisfy human appetites.

Evolution has equipped all of us humans and animals alike with the instinct to survive, thrive, procreate, and avoid pain and misery. This provides us with a scientific foundation to argue that reducing the pain, suffering and misery of others not only humans is the moral, appropriate, rational and prosocial thing to do. If we can live happy, healthy and productive lives without harming others, why wouldnt we?

World Day for the End of Speciesism is observed on August 29 annually. It is a day for us to reflect on and challenge our long-held beliefs about the superiority of humans, and how to relate to and regard non-human species. The Selangor SPCA, long seen as an organisation working to protect and improve the welfare of companion animals, such as cats and dogs, has expanded its work to include advocating improvements to farm animals welfare, and a plant-based lifestyle and ethics. On this day, we encourage everyone to change how we view and treat other species, take measures to reduce the suffering of other species, reduce the consumption of meat and animal products, even if one cannot make the full transition to a vegetarian or vegan diet, support higher welfare standards for farm animals until the animal agriculture system can be reformed or abolished, question traditions and practices that exploit or harm animals, and choose products, services and practices that cause the least harm to others. September 2, 2020.

* Wong Ee Lynn is farm animal welfare programme manager at the Selangor Society for the Prevention of Cruelty to Animals.

* This is the opinion of the writer or publication and does not necessarily represent the views of The Malaysian Insight.

See more here:
Show speciesism the door - The Malaysian Insight

Boris the polar bear, the oldest male of his species in human care, euthanized at Point Defiance Zoo – Q13 FOX

Boris the polar bear euthanized at Point Defiance Zoo

Boris was the oldest male of his species in human care

TACOMA, Wash. - Boris, an elderly polar bear believed to be the oldest male of his species on the planet,was humanely euthanizedat Point Defiance Zoo & Aquarium on Sept. 1 following a significant decline in his health.

He was34 and a one-time circus bear who found a stable home in Tacoma, where he was loved and revered by the community. He gained international recognitionsevenyears ago when photographs of him undergoing a dental procedure at Point Defiance Zoo circulated in newspapers and online around the world.

(Photo/Ingrid Barrentine)

Zoo staff members made the difficult decision to euthanize the geriatric bear due to his deteriorating quality of life, Point Defiance Zoo & Aquarium Head Veterinarian Dr. Karen Wolf said.

This is a very sad day for us, said Alan Varsik, director of Zoological and Environmental Education for Metro Parks Tacoma. Borisheld a special place in the hearts of our staff and our community. We were pleased we could give him a home when he was rescued from the circus. But we are even happier thatBorisbecame a beloved ambassador for his species, inspiring our guests to take action that can help polar bears in the wild.

Point Defiance Zoo & Aquarium gaveBorisa home in 2002 when he was a scrawny, malnourished and mistreated animal seized by the U.S. Fish & Wildlife Service from a traveling circus after it stopped in the U.S. territory of Puerto Rico. Zoos across the nation stepped up to takeBorisand five other bears, providing homes, proper nutrition and expert care.Boriswas the last surviving member of that group.

(Photo/Ingrid Barrentine)

At 34,Borishad far surpassed the median life expectancy of 23.4 years for male polar bears in human care. (They generally live about 15-18 years in the wild.) According to data from zoos in North America and around the world,Boriswas the oldest male of his species on record.

Recent exams showed significant arthritis in several ofBoris joints, several fused vertebrae in his neck and skin issues, Wolf said. He also had a history of gastrointestinal problems, dental and liver disease.

In late 2017,Borisbecame a medical pioneer when stem cells grown from his own fat tissue were used in an attempt to treat his arthritis. Wolf enlisted the aid of Colorado State University researcher Dr. Valerie Johnson to help treatBoris. Johnson has successfully used stem-cell therapy in other animals, but its believedBoriswas the first polar bear to receive the protocol.

Borisparticipated in his medical care, learning to stick a paw through a specially built sleeve in his bedroom so veterinary staff could get the voluntary blood samples that were critical to monitoring his health.

Keepers also played a big role in givingBorisa healthy, comfortable life, giving him his favorite foods and daily enrichments like a denfull of fresh wood wool shavings daily to roll in. Despite moving slowly on land, he enjoyed splashing in the deep saltwater pool, batting and diving onto an array of barrels, cans and balls offered by keepers.

(Photo/Ingrid Barrentine)

He also enjoyed the occasional mouth-wrestle with his 24-year-old polar bear buddy Blizzard.

We tookBorisfrom a bad scenario to a place where he had a better life, and where he could be an ambassador for the Arctic, said staff biologist Mike Messersmith, who had cared forBorissince his arrival in Tacoma. He inspired people to help save his species by taking actions to slow climate change.

Polar bears are protected by the U.S. Marine Mammal Protection Act and listed as a threatened species under the U.S. Endangered Species Act. Their existence is threatened by the warming of the ocean, which robs them of the sea ice from which they hunt for seals and other food. Point Defiance Zoo has been home to polar bears for more than 80 years, and is a partner with Polar Bears International as an Arctic Ambassador Center.

Point Defiance Zoo & Aquariums other polar bear, Blizzard, 24, continues to live in the Arctic Tundra habitat, helping guests learn about his species.

Zoo guests can sign a giant card for his caregivers in memory ofBorisin the main plaza Sept. 2-4.

Donations inBoris memory can be made to help polar bear conservation by donating to the Dr. Holly Reed Wildlife Conservation Fund, administered by The Zoo Society.

Read the original:
Boris the polar bear, the oldest male of his species in human care, euthanized at Point Defiance Zoo - Q13 FOX

UC Davis Sets Record With $941 Million in Research Funding – UC Davis

The University of California, Davis, set a new record for external research funding in fiscal year 2019-20, receiving $941.2 million in awards, a $94.5 million increase from the previous record set in 2018.

The awards reflect a broad range of critical work, from therapies for pancreatic cancer and disability research to new online learning platforms and tackling issues related to climate change, such as wildfire smoke and the spillover of zoonotic diseases.

This new record validates how UC Davis is sought more than ever to find solutions for the worlds most critical issues, Chancellor Gary S. May said. During these historic times, our collaborative research community is eager to make breakthroughs in health, environmental sustainability, education and so much more.

The largest increases in funding compared to the previous year were in the College of Engineering (up $60 million), Betty Irene Moore School of Nursing (up $40 million) and College of Agricultural and Environmental Sciences (up $29 million). (Reports are based on the principal investigators school or college.)

UC Davis researchers also applied their unique areas of expertise to tackling the COVID-19 pandemic. More than two dozen grants totaling $2.4 million were awarded during fiscal year 2019-20, which ended June 30.

COVID-19 grants have funded multiple clinical trials and the development of novel vaccine strategies, as well as launching new studies on poverty and social distancing, the impact of online learning, community spread and mitigation measures, and predicting potential mutations of the virus, among others.

Our researchers eagerness and ability to quickly respond to the pandemic is a testament to their passion and mission-driven focus to provide critical insight and solutions that help our global community, said Prasant Mohapatra, vice chancellor for research. Right from the onset of the pandemic, we witnessed an inspiring level of collaboration across different areas of expertise, including between the School of Medicine and researchers on the campus in Davis.

In general, the level of research funding associated with cross-disciplinary research units, where experts from different fields of study collaborate on projects, has been one of the fastest growing segments over the last five years climbing 162 percent. One of these units, the California National Primate Research Center, received a $3.8 million award to develop a model to study early Alzheimers disease. Another, the Air Quality Research Center, received $3.75 million for the assessment and mitigation of wildfire-induced air pollution.

The federal government remains the top funder for research at UC Davis, making up half the total awards with a slight increase to $477 million in total grants. Funding from the National Institutes of Health was the highest funder at $251.5 million, with awards from the National Science Foundation totaling $44.7 million and awards from the U.S. Department of Agriculture totaling$39.7 million.

State funding rose slightly to $132 million, with $53.7 million in research funding from the Department of Transportation, $34.5 million from the Department of Food and Agriculture and $22.1 million from the Resources Agency.

UC Davis also saw significant increases from other funders, including a $37.5 million increase in foundation funding for a total of $47.5 million; a $25.7 million increase in other government funding totaling $45.6 million; and an $11 million increase in business funding, which totaled $85.4 million in awards for fiscal year 2019-20.

Where funds are awarded up-front to cover several years, the money is counted in the first year the award was received. Incrementally funded awards are counted as authorized in each year.

Research enabled by this funding not only helps to better understand and solve issues facing our society, but also leads to new innovations, products and startup companies each supporting economic growth. Over the last fiscal year, 15 emerging startups licensed foundational technology developed at UC Davis. Researchers also submitted 141 invention disclosures and were awarded 89 domestic and foreign patents that same year.

Read more here:
UC Davis Sets Record With $941 Million in Research Funding - UC Davis

Back to Top